Novo Nordisk U.S. President Dave Moore confirms the company is in active discussions with the Trump administration over most favored nation pricing for its popular GLP-1 drugs Ozempic and Wegovy, as it wraps up talks for the IRA Medicare drug price negotiations. It comes as the company is ramping up its U.S. manufacturing capabilities ahead of the anticipated approval of Wegovy in pill form. Moore spoke exclusively with CNBC’s Bertha Coombs at the HLTH conference in Las Vegas

See Full Page